Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
86.46
+1.42 (1.67%)
At close: May 1, 2026, 4:00 PM EDT
85.56
-0.90 (-1.04%)
After-hours: May 1, 2026, 7:48 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 63 employees as of December 31, 2025. The number of employees increased by 2 or 3.28% compared to the previous year.
Employees
63
Change (1Y)
2
Growth (1Y)
3.28%
Revenue / Employee
$876,698
Profits / Employee
-$2,604,381
Market Cap
2.92B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 2 | 3.28% |
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Beam Therapeutics | 511 |
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Structure Therapeutics | 220 |
| Soleno Therapeutics | 182 |
| Tango Therapeutics | 137 |
NKTR News
- 1 day ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 days ago - Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets - PRNewsWire
- 5 days ago - Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers – NKTR - GlobeNewsWire
- 5 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR - PRNewsWire
- 10 days ago - Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 11 days ago - Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering - PRNewsWire
- 13 days ago - Nektar Therapeutics Announces Proposed Public Offering - PRNewsWire
- 13 days ago - This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness. - Barrons